🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

It’s our first interview day of 2022-2023!! Can’t wait to meet applicants and share more about our program youtu.be/74VvN-CsRVA

Swinging into interview season like woah! Pictured is Yellow Firm out at Topgolf ⛳️🏌️‍♀️🏌️‍♂️🏌️last night. In the words of Michael Scott (or maybe it was Wayne Gretzky), you miss 100% of the shots you don’t take) 😂

A belated congrats to the newly minted Fred Hutch Cancer Center UW Medicine heme/onc fellows!! All-star cast including Hannah Abrams, Simone Dekker, MD, PhD, Margery Gang, Asra Shaik, & more 🤩 Excited to welcome you to Seattle! Cc Jordan Gauthier Brenda M Sandmaier, MD, FASTCT Gary Lyman 🇺🇸🇪🇺🇺🇦💛💙 Dr K., MD, MS, FASCO 🌎🇺🇸🇪🇺🇺🇦🌏 et al 💪

Had a fantastic time presenting our work and was very excited to see so much interest from the audience!#ASH22 #leusm #bmtsm

Amazing #OHSUscholarship on display at #ash2022!

Looking forward to presenting 3 abstracts on behalf of our group at #Tandem23! Lori Muffly Simone Dekker, MD, PhD Jean Michael Garcia Sabile, MD Stanford BMT & Cell Therapy OHSU Knight Cancer Institute Fred Hutch Cancer Center ASTCT CIBMTR

Pre-transplant MRD discordance in 39% of cases comparing BCR/ABL RT-PCR vs ClonoSeq NGS in ALL (p190 and p210). Worse outcomes for NGS positive. So interesting! Dekker, et al. 128 #Tandem23 #Leusm #BMTsm

Aaron Logan, MD, PhD, MPhil thanks for tweeting this. As an ALL doc and avid Adaptive Biotech user, it’s important for clinicians to be aware of this finding and not jump the gun on intervening on non-IgH “positive MRD” in B-ALL.

The best part of academic medicine is this! More to come! Marlise R. Luskin MD, MSCE Ryan Cassaday Anand Patel Adam DuVall MD, MPH

MRD Detection Provides Prognostic Value in Patients With ALL Undergoing HCT Emily Liang ASTCT CIBMTR #Tandem23 onclive.com/view/mrd-detec…

Patients who underwent hematopoietic cell transplant for #ALL who had low MRD were more likely to relapse versus those with undetectable MRD pre-HCT. #Tandem23 | ASTCT Fred Hutch Cancer Center ow.ly/XrGY50MUEgE

blessed to bring home the W with these handsome nerds in ACP Oregons Doc’s Dilemma 🎉 🫡OHSU IM Residency ACP

Congrats to the Oregon team for taking home the Osler Cup for winning #DoctorsDilemma, ACP’s Jeopardy-styled medical knowledge competition, at #IM2023 in San Diego 🏆 Drs. Doug Rice, Arjun Panda, and @gabrielkmonti from OHSU IM Residency OregonACP

Our study of NGS-based MRD in HCT for adult ALL is published! Pre-HCT MRD even at low levels <10-4 and post-HCT MRD predicted relapse. In B-cell ALL, IgH clonotypes, rather than non-IgH, were associated with relapse. (1/3) ashpublications.org/bloodadvances/…

really enjoyed this review of all things MRD for AML, AML, ALL, & CML by Simone Dekker, MD, PhD et al! ascopubs.org/doi/10.1200/ED…

I'm excited to share PRIMeD! It's an awesome opportunity for recent PhD or MD graduates to visit @FredHutch, present your work, and learn about #immunology, #oncology and #DataScience! Deadline is July 15; please apply! fredhutch.org/en/events/prim…

Detectable pre-HCT MRD, even at a low level of <10–4, and any detectable post-HCT MRD increase the risk of post-HCT relapse. loom.ly/J0JEHpE #clinicaltrialsandobservations #lymphoidneoplasia #transplantation

Great work led by Emily Liang Simone Dekker, MD, PhD Lori Muffly #leusm

Learn more about the use of #MRD to optimize management of #AML, #ALL, and #CML by checking out our new #ASCOEdBook review on this emerging topic! fal.cn/3Afvu #ASCO #LEUSM Simone Dekker, MD, PhD #ASCO23

Thank you to First Lady Melania Trump for visiting Fred Hutch's South Lake Union campus to highlight the importance of supporting #cancersurvivors through specialized care and research, including survivors of #childhoodcancers and #breastcancer as part of the #CancerMoonshot.